A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
about
Characterization of the time course of carbamazepine deinduction by an enzyme turnover modelVatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications.Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients.Metabolism and transport of oxazaphosphorines and the clinical implications.Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer managementPopulation pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorptionModel-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology GroupA strategy for residual error modeling incorporating scedasticity of variance and distribution shape.Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats.Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation.Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat.Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam.Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.Prognostic significance of leukopenia during the induction phase in adult B cell acute lymphoblastic leukemia.Population pharmacokinetics of artemether, dihydroartemisinin and lumefantrine in Rwandese pregnant women treated for uncomplicated malaria
P2860
Q34156256-AB66C0C6-C187-4446-8406-86BF95CDFE50Q34570873-39A05CB0-B07F-4660-B19A-C578B7F336F7Q34682560-078F56C8-C0C7-4001-A5B3-3B8FD4BF79F2Q35058030-96F18501-E55C-4C4C-A44D-52A27BB06E7AQ35826366-C5B9AFE1-CD4B-4F12-84E5-2A517D964EF9Q35826682-615C7377-5356-4BA8-8A85-3BA5C22902E4Q35867335-49318C05-C4E4-4006-AB44-D28FB470DC8FQ36360811-2423B9DB-0484-40E9-A258-E3E3A6E35C45Q36441485-AA6B7DE6-1D07-4FA1-8925-C6BADF971C66Q36702972-5912AB25-0804-4933-8DD8-FC0389249342Q37026667-6071C5C5-370E-49AF-9B35-ADAB334C536FQ37120672-60E3D52F-BA46-468C-96CE-3973B62E7D06Q38996409-B6540EAE-355E-4BA4-84A1-67E2C615549AQ39767125-BA837CCD-1B53-49D0-AAAD-14C82D7DBB31Q44028238-8BCC2D46-80F5-4C4B-9F85-00B73179BDF7Q44444134-9AE6EE9F-F5D4-4DF7-80C9-08A1090C561DQ44661102-D7233C9E-AB5F-41D5-997C-9F397EAB6659Q46601104-603A0E6A-0FB0-4093-821B-D6DCE9F94A25Q47890270-A1C83A08-6A35-4ABE-80DA-C7A09CD38426Q48353602-E4FE192E-3508-4151-A413-5D937B4F1F40Q52599791-E90A69A3-5F3D-4E06-A7DE-2A4C8BA080B7Q56354961-B440540F-8103-4360-AEB1-4B89E25BE0F7
P2860
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@ast
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@en
type
label
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@ast
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@en
prefLabel
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@ast
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@en
P2093
P2860
P1476
A mechanism-based pharmacokine ...... ion in breast cancer patients.
@en
P2093
B Björkstrand
M Abdel-Rehim
M Bielenstein
M Johansson
M O Karlsson
U S Svensson
P2860
P304
P356
10.1046/J.1365-2125.1999.00090.X
P407
P50
P577
1999-11-01T00:00:00Z